文献速递糖尿病肥胖与代谢综合征

非裔美国患者非酒精性脂肪性肝炎的临床与组织学特征

Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.
PubMed 文献 · Diabetes Care · 2017-11-13

本研究将67例非裔美国患者按年龄、性别、BMI、糖化血红蛋白和2型糖尿病患病率以2:1匹配134例白人,用质子磁共振波谱测肝内甘油三酯并做肝活检。非裔美国人肝内甘油三酯较低(6.1±6.8% vs 9.4±7.5%,P=0.007),NAFLD较少(25.0% vs 51.9%,P=0.003);但NAFLD患者中NASH患病率无差异(57.1% vs 73.3%,P=0.12),组织学严重程度相似。

要点

  • 非裔美国人肝内甘油三酯低于白人(6.1±6.8% vs 9.4±7.5%,P=0.007),NAFLD患病率较低(25.0% vs 51.9%,P=0.003)。
  • NAFLD患者中NASH患病率无种族差异(57.1% vs 73.3%,P=0.12),炎症、气球样变和纤维化严重程度相似。
  • 作者认为非裔美国人一旦发生NAFLD,应按与白人同等力度筛查NASH。

核心结论

  • 非裔美国人肝内甘油三酯蓄积较低,但一旦发生NAFLD,NASH的发生率和严重程度与白人患者相似。
  • 作者认为非裔美国人NAFLD患者应按与白人患者同等临床力度筛查NASH。

研究设计与样本

  • 67例非裔美国患者按年龄、性别、BMI、糖化血红蛋白和2型糖尿病患病率以2:1匹配134例白人。
  • NASH筛查包括质子磁共振波谱(1H-MRS)测肝内甘油三酯,有肝脂肪变者行肝活检。
  • 口服葡萄糖耐量试验中用Matsuda指数评估胰岛素抵抗。

主要发现

  • 非裔美国人肝内甘油三酯低于白人(均值±SD 6.1±6.8% vs 9.4±7.5%,P=0.007)。
  • 非裔美国人NAFLD患病率低于白人(25.0% vs 51.9%,P=0.003)。
  • NAFLD患者中NASH患病率两族无差异(57.1% vs 73.3%,P=0.12),各组织学参数严重程度相似。
  • NAFLD患者中胰岛素抵抗两族相似(Matsuda指数3.3±1.8 vs 3.1±1.9,P=0.61;Adipo-IR 5.7±4.6 vs 6.4±4.7 mmol/L·µU/mL,P=0.53)。
  • 无NAFLD者中非裔美国人胰岛素抵抗似更重(Matsuda指数4.9±3.6 vs 7.0±4.9,P=0.11;Adipo-IR 3.9±2.8 vs 2.7±2.3 mmol/L·µU/mL,P=0.06)。

临床怎么用

  • 作者认为非裔美国人NAFLD患者应按与白人患者同等临床力度筛查NASH。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There has been a widespread misconception among physicians that African Americans are protected from developing nonalcoholic steatohepatitis (NASH). However, a formal histologic and metabolic comparison against well-matched Caucasians has never been performed. RESEARCH DESIGN AND METHODS: Sixty-seven African American patients were matched 2:1 to Caucasians (n = 134) for age, sex, BMI, hemoglobin A1c, and prevalence of type 2 diabetes mellitus (T2DM). Screening for NASH included measurement of intrahepatic triglyceride content by proton MRS (1H-MRS), followed by a liver biopsy if patients had hepatic steatosis. Insulin resistance was estimated during an oral glucose tolerance test using the Matsuda Index. RESULTS: Compared with Caucasians, African American patients had a lower intrahepatic triglyceride content (mean ± SD 6.1 ± 6.8% vs. 9.4 ± 7.5%, P = 0.007) and the presence of nonalcoholic fatty liver disease (NAFLD) was less common (25.0% vs. 51.9%, P = 0.003). However, prevalence of NASH was not different between ethnicities in patients with NAFLD (57.1% vs. 73.3%, P = 0.12). Moreover, they showed similar severity in each of the individual histologic parameters (inflammation, ballooning, and fibrosis). Among patients with NAFLD, insulin resistance was similar between both ethnic groups (Matsuda Index: 3.3 ± 1.8 vs. 3.1 ± 1.9, P = 0.61; adipose tissue insulin resistance [Adipo-IR] index: 5.7 ± 4.6 vs. 6.4 ± 4.7 mmol/L ⋅ µU/mL, P = 0.53) but appeared to be worse in African American versus Caucasian patients without NAFLD (Matsuda Index: 4.9 ± 3.6 vs. 7.0 ± 4.9, P = 0.11; Adipo-IR: 3.9 ± 2.8 vs. 2.7 ± 2.3 mmol/L ⋅ µU/mL, P = 0.06). African American patients also had lower plasma triglycerides and higher HDL cholesterol, independent of the severity of intrahepatic triglyceride. CONCLUSIONS: Although African Americans have lower intrahepatic triglyceride accumulation, once NAFLD develops, NASH occurs as frequently, and as severe, as in Caucasian patients. Therefore, African Americans with NAFLD should be screened for NASH with the same degree of clinical resolve as in Caucasian patients.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bril F, Portillo-Sanchez P, Liu IC, et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care. 2017. PMID: 29133343. doi:10.2337/dc17-1349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。